Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 18 of 18 in Reminyl, Galantamine (generic)

  1. Positive Phase 1a Outcome For Memogain??Read the original story

    Tuesday Sep 9 | BioSpace

    Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain's potential benefits over existing Alzheimer's drugs; * increased safety in the absence of significant side effects, * more potent cognitive enhancement. The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered MemogainA in healthy young and elderly subjects, compared to the daily recommended doses of the current Alzheimer's drugs: galantamine and donepezil .

    Comment?

  2. Positive Phase 1a Outcome for MemogainRead the original story

    Tuesday Sep 9 | Customer Interaction Solutions

    Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain's potential benefits over existing Alzheimer's drugs; The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered Memogain in healthy young and elderly subjects, compared to the daily recommended doses of the current Alzheimer's drugs: galantamine and donepezil . Study participants were additionally tested for improved cognition.

    Comment?

  3. Use of cognitive enhancers for mild cognitive impairment: protocol...Read the original story

    Sunday Aug 17 | CiteULike

    Elderly individuals who have memory problems without significant limitations in activities of daily living are often diagnosed as having mild cognitive impairment .

    Comment?

  4. Galantamine for Alzheimer's disease and mild cognitive impairment.Read the original story

    Aug 13, 2014 | CiteULike

    Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor.

    Comment?

  5. Proneurogenic Group II mGluR antagonist improves learning and reduces ...Read the original story

    Aug 12, 2014 | Molecular Psychiatry

    Correspondence: Dr S Gandy, James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA.

    Comment?

  6. 3.5 million for Exeter team's national health technology assessment workRead the original story w/Photo

    Aug 1, 2014 | Mid Devon Star

    A TEAM at the University of Exeter Medical School has been awarded A 3.5 million to continue providing high-quality evidence to help the National Institute for Health and Care Excellence form key decisions on healthcare.

    Comment?

  7. 3.5 million for Exeter team's national health technology assessment workRead the original story w/Photo

    Jul 30, 2014 | Mid Devon Star

    A TEAM at the University of Exeter Medical School has been awarded A 3.5 million to continue providing high-quality evidence to help the National Institute for Health and Care Excellence form key decisions on healthcare.

    Comment?

  8. Galantamine promotes adult hippocampal neurogenesis via M1 muscarinic ...Read the original story

    Jul 25, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  9. Why Alzheimer's Drugs Keep FailingRead the original story

    Jul 14, 2014 | Scientific American

    Drug candidates have a 99.6 percent failure rate, and poor early detection methods make clinical trials difficult and costly Areas of cell loss are in red on this brain scan of an older person with Alzheimer's disease.

    Comment?

  10. Renewed focus on dementia checked by drug challengesRead the original story w/Photo

    Jul 3, 2014 | Chemistry World

    Efforts to target amyloid protein plaques, thought to be responsible for Alzheimer's disease, have run into trouble Science Photo Library The world needs to tackle head-on the market failures undermining dementia research and drug development, UK Prime Minister David Cameron told a summit of world health and finance leaders in London in ... (more)

    Comment?

  11. The Natural Products Association (NPA) welcomed Devon Powell as its new senior vice presidentRead the original story

    Jul 2, 2014 | HAPPI/Household & PP Industry

    The Natural Products Association : welcomed Devon Powell as its new senior vice president of member services and chief operating officer .

    Comment?

  12. Kraft Foods Takes on New Vice ChairmanRead the original story

    Jun 6, 2014 | Refrigerated & Frozen Foods

    National Frozen & Refrigerated Foods Association, Harrisburg, Pa . Natalie Markle was added to the newly created position of member communications coordinator, responsible for marketing member resources and events, developing and maintaining an online and social media presence for members and engaging members in NFRA's PR and promotion efforts.

    Comment?

  13. A Randomized, Placebo-Controlled Study Investigating the Nicotinic...Read the original story

    May 14, 2014 | Neuropsychopharmacology

    We'd like to invite you to take part in our annual reader survey. As a thank you for your participation you will have the opportunity to enter a prize draw to win a MacBook Air.

    Comment?

  14. NPA Taps Former FDA ChiefRead the original story

    Jun 3, 2014 | HAPPI/Household & PP Industry

    The Natural Products Association : hired Corey Hilmas, MD, Ph.D., to serve as its new senior vice president of scientific and regulatory affairs.

    Comment?

  15. slider_May2014_TorosyanRead the original story

    May 9, 2014 | Applied Radiology

    Alzheimer's disease is the most common neurodegenerative disorder, and cases of AD continue to rise, posing a significant clinical and financial challenge for the upcoming years.

    Comment?

  16. Pharmacological Dissociation of Novelty Responses in the Human BrainRead the original story

    Apr 7, 2014 | Cerebral Cortex

    Address correspondence to Dr Nico Bunzeck, Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.

    Comment?

  17. Impaired working memory by repeated neonatal MK-801 treatment is...Read the original story

    Mar 13, 2014 | CiteULike

    European journal of pharmacology , Vol. 725 , pp. 32-39, doi:10.1016/j.ejphar.2014.01.007 Early life blockade of the NMDA receptor by using MK-801, a non-competitive NMDA receptor antagonist, induces behavioral changes that mimic several features of schizophrenia.

    Comment?

  18. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex.Read the original story

    Mar 13, 2014 | CiteULike

    The tryptophan metabolite kynurenic acid is an endogenous antagonist of the I 7 nicotinic acetylcholine receptor and, at higher concentrations, inhibits ionotropic glutamate receptors.

    Comment?